VIDEOS FROM EXPERTS & PATIENTS

Albuterol-Only Rescue Is Incomplete Transcript

Graphic on screen: AIRSUPRA logo, text, and Dr Smith image animate on screen.

Text on screen: PRESENTS SUPRASESSIONS with Dr Alexis Smith

Graphic on screen: Dots fill the frame. Copy appears in the center.

Text on screen: SESSION 1: ALBUTEROL-ONLY RESCUE IS INCOMPLETE

Graphic on screen: Copy builds in the center of the frame, and a line animates around the copy.

Text on screen: RETHINKING YOUR APPROACH TO ASTHMA RESCUE: IS ALBUTEROL-ONLY RESCUE ENOUGH?

Dr Alexis Smith: Asthma doesn’t take a season off. Throughout the year, factors like respiratory infections, allergens, and environmental changes can increase symptoms and the risk of exacerbations, regardless of asthma severity.

Graphic on screen: Camera cuts to Dr Smith. Text builds next to Dr Smith, and a line animates around the copy.

Text on screen: Dr Alexis Smith, DO Pulmonologist

Dr Alexis Smith: Hello, I’m Dr Alexis Smith, a practicing pulmonologist. Thank you for joining me. In this video, I’m going to share with you some information you may not be aware of about albuterol-only rescue—or short-acting beta₂-agonists, or SABAs for short.

Graphic on screen: Text disappears as Dr Smith continues to speak.

Dr Alexis Smith: You may be asking yourself—why are we talking about something that’s been the standard of care in asthma rescue for decades?

Graphic on screen: Dots fill the frame. Copy appears in the center. A line animates around the copy. The dots float in the space around the text.

Text on screen: ALBUTEROL-ONLY RESCUE IS INCOMPLETE

Dr Alexis Smith: Well, you see, albuterol-only rescue is incomplete.

Graphic on screen: Dots fill the frame and the background color lightens. Copy appears in the center. A line animates around the copy. The dots float in the space around the text.

Text on screen: LET’S BEGIN BY LOOKING AT WHAT’S DRIVING ASTHMA SYMPTOMS

Dr Alexis Smith: Let’s begin by looking at what’s driving asthma symptoms.

Graphic on screen: Camera cuts to Dr Smith.

Dr Alexis Smith: Asthma is unpredictable, with symptoms driven by both bronchoconstriction and inflammation.

Graphic on screen: Dots fill the frame, then part to reveal copy in the center and 4 icons. Icon labels animate in, with a line animating around each label. Each icon/label pair animates as the VO mentions the corresponding trigger. Icons float continuously throughout the scene.

Text on screen: ASTHMA TRIGGERS
VIRAL INFECTIONS
PET DANDER
WEATHER CHANGES
POLLEN

Asthma triggers vary from person to person. This is not a complete list.

Dr Alexis Smith: Patients can experience symptoms triggered by viral infections, weather changes, or allergens such as pet dander or pollen.

Graphic on screen: Camera cuts to Dr Smith.

Dr Alexis Smith: This applies to all patients, including those whose asthma is well controlled on maintenance therapy and who are considered at low risk of an exacerbation.

Graphic on screen: The camera then zooms in to show immune cells. The immune cells release cytokines as more immune cells come into the frame and release more cytokines.

Text on screen: IMMUNE CELL

CYTOKINES

Hypothetical illustration of asthmatic airway.

Dr Alexis Smith: When the body is exposed to triggers, inflammatory mediators such as cytokines are released, activating immune cells in the airway.

Graphic on screen: Camera cuts to an asthmatic airway. The airway narrows from bronchoconstriction and swells from inflammation.

Text on screen: Airway inflammation

Bronchoconstriction

Hypothetical illustration of asthmatic airway.

Dr Alexis Smith: This results in airway inflammation and bronchoconstriction that drive...

Graphic on screen: Camera cuts to a patient struggling to breathe. Text animates on screen, outlined by a moving line. As the line reaches the word “SYMPTOMS”, the list of symptoms appears.

Text on screen: ASTHMA SYMPTOMS
WHEEZING
COUGHING
CHEST TIGHTNESS
SHORTNESS OF BREATH

Not an actual patient.

Dr Alexis Smith: ...symptoms, including wheezing, coughing, chest tightness, and shortness of breath.

Graphic on screen: Camera cuts to Dr Smith.

Dr Alexis Smith: While albuterol-only rescue treats bronchoconstriction, it does not address the underlying inflammation.

Graphic on screen: Camera cuts back to the asthmatic airway. Text animates around the airway, while lines animate around the descriptions.

Text on screen: Smooth muscle tightening

Swelling and thickening of the airway wall

Mucus overproduction narrowing the airway lumen

Hypothetical illustration of asthmatic airway.

Dr Alexis Smith: Inflammation contributes to:

• Smooth muscle tightening

• Swelling and thickening of the airway wall, and

• Mucus overproduction narrowing the airway lumen

Graphic on screen: Camera cuts to Dr Smith.

Dr Alexis Smith: Together, the effects of inflammation can lead to worsening symptoms and potentially an exacerbation.

Graphic on screen: Camera cuts to a patient’s hand reaching for inhaler.

Dr Alexis Smith: In response, patients often reach for their rescue inhalers…

Graphic on screen: Camera cuts to Dr Smith.

Dr Alexis Smith: ...for relief, without addressing the inflammation that’s central to driving their symptoms.

Dr Alexis Smith: Let’s now turn to what global asthma experts say about albuterol-only rescue.

Graphic on screen: Dots fill the frame. Copy appears in the center. A line animates around the copy as the GINA logo appears next to it.

Text on screen: GINA NO LONGER RECOMMENDS TREATMENT OF ASTHMA WITH SABA ALONE

©Global Initiative for Asthma, all rights reserved.
Use is by express license from the owner.
SABA, short-acting β₂-agonist.

Dr Alexis Smith: The Global Initiative for Asthma (or GINA), a body of global asthma experts, including US experts, no longer recommends treatment of asthma with SABA alone.

Graphic on screen: Camera cuts to Dr Smith.

Dr Alexis Smith: While SABAs are effective symptom relief, the GINA 2025 Report states that the risk of asthma exacerbations and mortality is higher with increased SABA use, even in patients treated with SABA only.

Graphic on screen: Dots fill the frame, then reveal a dark background. Copy appears in the center. A line animates around the copy. Dots continue to float in the space around the text.

Text on screen: THE GINA 2025 REPORT SUPPORTS AN ANTI-INFLAMMATORY RESCUE APPROACH ACROSS ALL ASTHMA SEVERITIES

Dr Alexis Smith: Instead, GINA supports an anti-inflammatory rescue approach that treats both bronchoconstriction and inflammation across all asthma severities.

Graphic on screen: Camera cuts to Dr Smith.

Dr Alexis Smith: Is it time to rethink your approach to asthma rescue? Treat both bronchoconstriction and inflammation with an anti-inflammatory rescue approach.

Graphic on screen: Dots transition to create a dotted pattern in the corners of the frame and reveal the background color. Dots in corners animate. AIRSUPRA logo appears. Text animates into frame.

Text on screen: The first and only FDA-approved ANTI-INFLAMMATORY RESCUE that treats bronchoconstriction and helps prevent exacerbations

AIRSUPRA® (albuterol/budesonide) is a combination of albuterol, a beta₂-adrenergic agonist and budesonide, a corticosteroid, indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older.

Please continue to watch for full Important Safety Information.

Dr Alexis Smith: AIRSUPRA is the first and only FDA-approved ANTI-INFLAMMATORY RESCUE that treats bronchoconstriction and helps prevent exacerbations.

AIRSUPRA® (albuterol/budesonide) is a combination of albuterol, a beta₂-adrenergic agonist and budesonide, a corticosteroid, indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older.

Graphic on screen: Dots in corners animate. Text animates into frame.

Text on screen: AIRSUPRA CONTAINS SABA (albuterol) for rapid bronchodilation + ICS (budesonide) to address inflammation

ICS, inhaled corticosteroid; SABA, short-acting β₂-agonist.

Dr Alexis Smith: AIRSUPRA contains SABA (albuterol) for rapid bronchodilation and ICS (budesonide) to address the inflammation.

Graphic on screen: Dots in corners animate. Text and QR code animate into frame.

Text on screen: SCAN THIS CODE TO LEARN MORE ABOUT THE FIRST AND ONLY FDA-APPROVED ANTI-INFLAMMATORY ASTHMA RESCUE AT AIRSUPRAHCP.COM

Please see full Prescribing Information from your representative by visiting airsupraHCP.com.

Dr Alexis Smith: Scan this code to learn more about the first and only FDA-approved anti-inflammatory asthma rescue at airsupraHCP.com.

Graphic on screen: Scrolling ISI

Text on screen:

IMPORTANT SAFETY INFORMATION

• Contraindications: Hypersensitivity to albuterol, budesonide, or to any of the excipients

• Deterioration of Asthma: Asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient continues to experience symptoms after using AIRSUPRA or requires more doses of AIRSUPRA than usual, it may be a marker of destabilization of asthma and requires evaluation of the patient and their treatment regimen

• Paradoxical Bronchospasm: AIRSUPRA can produce paradoxical bronchospasm, which may be life threatening. Discontinue AIRSUPRA immediately and institute alternative therapy if paradoxical bronchospasm occurs. It should be recognized that paradoxical bronchospasm, when associated with inhaled formulations, frequently occurs with the first use of a new canister

• Cardiovascular Effects: AIRSUPRA, like other drugs containing beta,-adrenergic agonists, can produce clinically significant cardiovascular effects in some patients, as measured by pulse rate, blood pressure, and/or other symptoms. If such effects occur, AIRSUPRA may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST-segment depression. Therefore, AIRSUPRA, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension

• Do Not Exceed Recommended Dose: Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs

• Hypersensitivity Reactions, Including Anaphylaxis: Can occur after administration of albuterol sulfate and budesonide, components of AIRSUPRA, as demonstrated by cases of anaphylaxis, angioedema, bronchospasm, oropharyngeal edema, rash, and urticaria. Discontinue AIRSUPRA if such reactions occur

• Risk of Sympathomimetic Amines with Certain Coexisting Conditions: AIRSUPRA, like all therapies containing sympathomimetic amines, should be used with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus and in patients who are unusually responsive to sympathomimetic amines

• Hypokalemia: Beta-adrenergic agonist medicines may produce significant hypokalemia in some patients. The decrease in serum potassium is usually transient, not requiring supplementation

• Immunosuppression and Risk of Infections: Due to possible immunosuppression from the use of inhaled corticosteroids (ICS), potential worsening of infections could occur. Use with caution. A more serious or fatal course of chickenpox or measles can occur in susceptible patients

• Oropharyngeal Candidiasis: Has occurred in patients treated with ICS agents. Monitor patients periodically. Advise patients to rinse his/her mouth with water, if available, without swallowing after inhalation

• Hypercorticism and Adrenal Suppression: May occur with very high doses in susceptible individuals. If such changes occur, consider appropriate therapy

• Reduction in Bone Mineral Density: Decreases in bone mineral density have been observed with long-term administration of ICS. For patients at high risk for decreased bone mineral density, assess initially and periodically thereafter

• Glaucoma and Cataracts: Have been reported following the long-term administration of ICS, including budesonide, a component of AIRSUPRA

• Effects on Growth: Orally inhaled corticosteroids, including budesonide, may cause a reduction in growth velocity when administered to pediatric patients. The safety and effectiveness of AIRSUPRA have not been established in pediatric patients, and AIRSUPRA is not indicated for use in this population

• Most common adverse reactions (incidence ≥ 1%) are headache, oral candidiasis, cough, and dysphonia

• Drug Interactions: AIRSUPRA should be administered with caution to patients being treated with:

  • Strong cytochrome P450 3A4 inhibitors (may cause systemic corticosteroid effects)

  • Short-acting bronchodilators (concomitant use of additional beta-agonists with AIRSUPRA should be used judiciously to prevent beta-agonist overdose)

  • Beta-blockers (may block pulmonary effects of beta-agonists and produce severe bronchospasm)

  • Diuretics or non-potassium-sparing diuretics (may potentiate hypokalemia or ECG changes). Consider monitoring potassium levels

  • Digoxin (may decrease serum digoxin levels). Consider monitoring digoxin levels

  • Monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants (Use AIRSUPRA with extreme caution; may potentiate effect of albuterol on the cardiovascular system)

• Use AIRSUPRA with caution in patients with hepatic impairment, as budesonide systemic exposure may increase. Monitor patients with hepatic disease

INDICATION

AIRSUPRA is a combination of albuterol, a beta₂-adrenergic agonist and budesonide, a corticosteroid, indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older.

You are encouraged to report negative side effects of AstraZeneca prescription drugs by calling 1-800-236-9933. If you prefer to report these to the FDA, call 1-800-FDA-1088.

Please see full Prescribing Information, including Patient Information, by visiting airsupraHCP.com.

Announcer: AIRSUPRA Important Safety Information.

AIRSUPRA is contraindicated in patients with hypersensitivity to albuterol, budesonide, or any excipients.

Asthma may deteriorate acutely or chronically. Continued symptoms after AIRSUPRA or increasing doses of AIRSUPRA may be a marker of asthma destabilization and require evaluation of the patient and their treatment regimen.

AIRSUPRA can produce paradoxical bronchospasm, which may be life threatening. Discontinue AIRSUPRA immediately if paradoxical bronchospasm occurs. Paradoxical bronchospasm frequently occurs with the first use of a new canister of an inhaled formulation.

Drugs containing beta₂-adrenergic agonists can produce clinically significant cardiovascular effects in some patients. If these occur, consider discontinuation of AIRSUPRA. Beta-agonists have also been reported to produce ECG changes such as T-wave flattening, QTc interval prolongation, and ST-segment depression. Therefore, as with all sympathomimetic amines, AIRSUPRA should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.

Do not exceed recommended dose. Clinically significant cardiovascular effects and fatalities have been reported with excessive use of inhaled sympathomimetic drugs.

Hypersensitivity reactions including anaphylaxis can occur after administration of albuterol sulfate and budesonide, as demonstrated by cases of anaphylaxis, angioedema, bronchospasm, oropharyngeal edema, rash, and urticaria. Discontinue AIRSUPRA if these occur.

Like all therapies containing sympathomimetic amines, AIRSUPRA should be used with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus and those unusually responsive to sympathomimetic amines.

Beta-adrenergic agonists may produce significant hypokalemia in some patients. Decreased serum potassium is usually transient.

Due to possible immunosuppression from the use of ICS, worsening of infections can occur. A more serious or fatal course of chickenpox or measles can occur in susceptible patients.

Oropharyngeal candidiasis has occurred in patients treated with ICS agents. Monitor patients periodically. Advise patients to rinse their mouth with water without swallowing after inhalation.

Hypercorticism and adrenal suppression may occur with very high doses in susceptible patients. If these occur, consider appropriate therapy.

Decreases in bone mineral density have been observed with long-term administration of ICS. Regularly assess patients at high risk for decreased bone mineral density.

Glaucoma and cataracts have been reported following long-term administration of ICS, including budesonide.

Orally inhaled corticosteroids, including budesonide, may cause a reduction in growth velocity in pediatric patients. The safety and effectiveness of AIRSUPRA have not been established in pediatric patients and AIRSUPRA is not indicated for use in this population.

The most common adverse reactions are headache, oral candidiasis, cough, and dysphonia.

AIRSUPRA should be administered with caution to patients being treated with strong cytochrome P450 3A4 inhibitors, which may cause systemic corticosteroid effects; short-acting bronchodilators (concomitant use of additional beta-agonists with AIRSUPRA should be used judiciously to prevent beta-agonist overdose); beta-blockers, which may block pulmonary effects of beta-agonists and produce severe bronchospasm; diuretics or non-potassium-sparing diuretics, which may potentiate hypokalemia or ECG changes (consider monitoring potassium levels); digoxin, which may decrease serum digoxin levels (consider monitoring digoxin levels); mAOIs or tricyclic antidepressants. Use AIRSUPRA with extreme caution as these may potentiate the effect of albuterol on the cardiovascular system.

Use AIRSUPRA with caution in patients with hepatic impairment as budesonide systemic exposure may increase. Monitor patients with hepatic disease.

These are not all of the side effects for AIRSUPRA. Visit www.airsuprahcp.com for additional information, including full Prescribing Information and Patient Information.

Graphic on screen: Reference list animates in. AstraZeneca logo animates in the bottom left corner.

Text on screen:

REFERENCES

This product information is intended for US Healthcare Professionals only.

AIRSUPRA is a registered trademark of the AstraZeneca group of companies.

©2025 AstraZeneca. All rights reserved. US-96087 Last Updated 10/25

My Supra Story With Dr Neil Skolnik Transcript

Graphic on screen: Video title, disclaimer, logo, and photo of Dr Skolnik animate onto screen.

Text on screen: MY SUPRA STORY WITH DR. NEIL SKOLNIK

This Content is Intended for US Healthcare Professionals Only

Graphic on screen: Footage window animates on screen along with Dr Skolnik’s name and affiliations and a QR code with accompanying text.

Text on screen:

Dr. Neil Skolnik

Abington Family Medicine, Jenkintown, PA

Prof. of Family and Community Medicine, Sidney Kimmel Medical College of Thomas Jefferson University

Associate Director, Family Medicine and Residency Program at Jefferson Health - Abington

Text on screen: See Important Safety Information throughout and scan the QR code to see the Full Prescribing Information, including Patient Information, or visit airsuprahcp.com.

Dr Neil Skolnik: My name is Dr. Neil Skolnik, a practicing physician at Abington Family Medicine in Jenkintown, Pennsylvania. I am also a Professor of Family and Community Medicine at the Sidney Kimmel Medical College of Thomas Jefferson University, and Associate Director of the Family Medicine Residency Program at Jefferson Health - Abington. I've been in practice for over 30 years, and in those thirty years, I've seen patients across all asthma severities.

Graphic on screen: Airway image and text animate onto screen.

Text on screen: AIRWAY INFLAMMATION (label) and TIGHTENED SMOOTH MUSCLE (label)

Dr Neil Skolnik: It is well established that asthma is characterized by two main features, inflammation and bronchoconstriction. Patients do their best to avoid their asthma triggers, but sometimes that's not possible depending on their environment.

Text on screen: Shortness of breath
Cough
Chest tightness
AIRWAY INFLAMMATION (label) and TIGHTENED SMOOTH MUSCLE (label)

Dr Neil Skolnik: When patients experience symptoms, such as shortness of breath, cough, and chest tightness, they often reach for their rescue inhaler.

Text on screen: ALBUTEROL-ONLY RESCUE INHALERS TREAT BRONCHOCONSTRICTION BUT DON’T TREAT INFLAMMATION
AIRWAY INFLAMMATION (label) and TIGHTENED SMOOTH MUSCLE (label)

Dr Neil Skolnik: However, albuterol only addresses bronchoconstriction, and not inflammation, an underlying cause of asthma symptoms and exacerbations.

Graphic on screen: Text animates onto screen.

Text on screen: What does ‘shifting the paradigm’ in asthma rescue mean to you?

Graphic on screen: Footage window animates on screen and previous copy moves to the top left of the screen.

Text on screen: What does ‘shifting the paradigm’ in asthma rescue mean to you?

Dr Neil Skolnik: When I think about shifting the paradigm in asthma rescue, patients, and even my peers, need to understand that albuterol-only rescue is incomplete. We have historically treated symptoms with albuterol, not realizing that we need an asthma rescue approach designed to target inflammation and bronchoconstriction at the same time.

Graphic on screen: Text animates onto screen.

Text on screen: How has the management of asthma symptoms evolved over your career?

Graphic on screen: Footage window animates on screen, previous copy moves to the top left of the screen, and new copy appears next to Dr Skolnik.

Text on screen: How has the management of asthma symptoms evolved over your career?

Text on screen: GINA 2025 supports an anti-inflammatory rescue approach across all severities

Dr Neil Skolnik: Although the Global Initiative for Asthma, or GINA, first began recommending an anti-inflammatory rescue approach that could treat bronchoconstriction and inflammation in 2019, we lacked an FDA-approved option in the US, so we continued to rely on albuterol-only rescue to manage our patients’ symptoms.

Graphic on screen: Logo, QR code, and text callouts animate onto screen.

Text on screen: Inflammation + Bronchoconstriction

Text on screen: See Important Safety Information throughout and scan the QR code to see the Full Prescribing Information, including Patient Information, or visit airsuprahcp.com.

Dr Neil Skolnik: With AIRSUPRA, we finally have an on-label rescue approach designed to treat both inflammation and bronchoconstriction, in line with GINA recommendations. Let me tell you a little more about it.

Graphic on screen: Text and inhaler image animate onto screen. QR code and text callout remain on screen as text continues to build.

Text on screen: AIRSUPRA: FIRST AND ONLY FDA-APPROVED ANTI-INFLAMMATORY RESCUE DESIGNED TO TREAT BRONCHOCONSTRICTION AND HELP PREVENT EXACERBATIONS.

Text on screen: AIRSUPRA does not replace daily maintenance medication.

Text on screen: See Important Safety Information throughout and scan the QR code to see the Full Prescribing Information, including Patient Information, or visit airsuprahcp.com.

Dr Neil Skolnik: AIRSUPRA is the first and only FDA-approved anti-inflammatory rescue designed to treat bronchoconstriction and help prevent exacerbations.

Graphic on screen: Text continues to build, as SABA and ICS labels animate onto screen, while existing text, inhaler image, and QR code remain on screen.

Text on screen: AIRSUPRA CONTAINS

SABA (albuterol) for rapid bronchodilation
+
ICS (budesonide) to address inflammation

Dr Neil Skolnik: AIRSUPRA is a combination of albuterol, a beta₂-adrenergic agonist, and budesonide, a corticosteroid. AIRSUPRA was approved in 2023 for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older.

Graphic on screen: ISI builds onto screen.

Text on screen:

IMPORTANT SAFETY INFORMATION

• Contraindications: Hypersensitivity to albuterol, budesonide, or to any of the excipients

• Deterioration of Asthma: Asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient continues to experience symptoms after using AIRSUPRA or requires more doses of AIRSUPRA than usual, it may be a marker of destabilization of asthma and requires evaluation of the patient and their treatment regimen

• Paradoxical Bronchospasm: AIRSUPRA can produce paradoxical bronchospasm, which may be life threatening. Discontinue AIRSUPRA immediately and institute alternative therapy if paradoxical bronchospasm occurs. It should be recognized that paradoxical bronchospasm, when associated with inhaled formulations, frequently occurs with the first use of a new canister

• Cardiovascular Effects: AIRSUPRA, like other drugs containing beta₂-adrenergic agonists, can produce clinically significant cardiovascular effects in some patients, as measured by pulse rate, blood pressure, and/or other symptoms. If such effects occur, AIRSUPRA may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST-segment depression. Therefore, AIRSUPRA, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension

• Do Not Exceed Recommended Dose: Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs

Announcer: Important Safety Information.

AIRSUPRA is contraindicated in patients with hypersensitivity to albuterol, budesonide, or any excipients.

Asthma may deteriorate acutely or chronically. Continued symptoms after AIRSUPRA or increasing doses of AIRSUPRA may be a marker of asthma destabilization and require evaluation of the patient and their treatment regimen.

AIRSUPRA can produce paradoxical bronchospasm, which may be life threatening. Discontinue AIRSUPRA immediately if paradoxical bronchospasm occurs. Paradoxical bronchospasm frequently occurs with the first use of a new canister of an inhaled formulation.

Drugs containing beta₂-adrenergic agonists can produce clinically significant cardiovascular effects in some patients. If these occur, consider discontinuation of AIRSUPRA. Beta-agonists have also been reported to produce ECG changes such as T-wave flattening, QTc interval prolongation, and ST-segment depression. Therefore, as with all sympathomimetic amines, AIRSUPRA should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.

Do not exceed recommended dose. Clinically significant cardiovascular effects and fatalities have been reported with excessive use of inhaled sympathomimetic drugs.

Graphic on screen: Text animates onto screen.

Text on screen: Who is the right patient for AIRSUPRA?

Graphic on screen: Footage window and QR code with accompanying text animate onto screen, as previous copy moves to the top left of the screen.

Text on screen: Who is the right patient for AIRSUPRA?

Text on screen: See Important Safety Information throughout and scan the QR code to see the Full Prescribing Information, including Patient Information, or visit airsuprahcp.com.

Dr Neil Skolnik: After learning more about AIRSUPRA’s data, it became apparent to me that AIRSUPRA should be considered as asthma rescue therapy for all my adult asthma patients, aged 18 years and older, regardless of their asthma severity or background maintenance therapy.

AIRSUPRA provides the symptom relief that my patients are looking for while helping to protect them from exacerbations which we, as providers, know they need.

Graphic on screen: Text animates onto screen.

Text on screen: How do you talk to your patients about AIRSUPRA?

Graphic on screen: Footage window and QR code with accompanying text animate onto screen, as previous copy moves to the top left of the screen.

Text on screen: How do you talk to your patients about AIRSUPRA?

Text on screen: See Important Safety Information throughout and scan the QR code to see the Full Prescribing Information, including Patient Information, or visit airsuprahcp.com.

Dr Neil Skolnik: As a primary care physician, I see asthma patients across all severities. When I have a new patient with asthma come to the office, I consider starting AIRSUPRA for their asthma rescue.

When patients who are taking albuterol come into my office for a checkup, regardless of whether or not they’re on background maintenance therapy, I evaluate whether it makes sense to switch them from albuterol to AIRSUPRA.

I’ve found that my patients are very receptive to trying AIRSUPRA because the concept of an anti-inflammatory rescue is simple to understand.

Graphic on screen: Text animates onto screen.

Text on screen: What would you like your Primary Care colleagues to know about AIRSUPRA?

Graphic on screen: Footage window and QR code with accompanying text animate onto screen, as previous copy moves to the top left of the screen.

Graphic on screen: Text animates onto screen.

Text on screen: See Important Safety Information throughout and scan the QR code to see the Full Prescribing Information, including Patient Information, or visit airsuprahcp.com.

Dr Neil Skolnik: Being a primary care physician means that every day is busy, so it’s important that we always have the information we need to make the best decisions for our patients at our fingertips. Here’s what I would like my primary care colleagues to know about AIRSUPRA.

Graphic on screen: Logo appears at the top. Text animates onto screen in sync with Dr Skolnik's voice over. QR code and text callout remain on screen.

Text on screen: FDA-approved anti-inflammatory rescue

Dr Neil Skolnik: It’s an FDA-approved anti-inflammatory asthma rescue medication indicated for as-needed treatment or prevention of bronchoconstriction and to reduce exacerbation risk in patients who are 18 years of age or older.

Text on screen: Approved for use across all asthma severities

Dr Neil Skolnik: It is approved for use across all asthma severities as a rescue medication.

Text on screen: Can be used regardless of the patient’s background maintenance therapy

Dr Neil Skolnik: It can be used regardless of the patient’s background maintenance therapy.

Text on screen: Designed to address bronchoconstriction and inflammation

Dr Neil Skolnik: It is designed to address 2 key contributors to asthma symptoms: bronchoconstriction and inflammation.

Text on screen: Contains albuterol plus budesonide, a corticosteroid

Dr Neil Skolnik: It contains the albuterol your patients are familiar with, plus budesonide, a corticosteroid; and…

Text on screen: GINA 2025 supports an anti-inflammatory rescue approach across all severities

Dr Neil Skolnik: …use of AIRSUPRA is in line with the 2025 GINA report that supports an anti-inflammatory rescue approach across all asthma severities.

Graphic on screen: Text animates onto screen.

Text on screen: What do you tell patients who want to know more about coverage for AIRSUPRA?

Graphic on screen: Co-pay card image, text, and QR code animate onto screen.

Text on screen: Eligible commercially insured patients

PAY AS LITTLE AS $0* PER INHALER
Can be used for multiple inhalers at once. ^†

^*Terms and conditions apply. Government restrictions exclude people enrolled in federal government insurance programs from co-pay support.

^†Pending insurance requirements.

Dr Neil Skolnik: AIRSUPRA has a patient access program that features a $0 co-pay card to make AIRSUPRA accessible for the majority of commercially insured patients. My patients have found the co-pay card to be helpful.

Graphic on screen: Footage window, logo, and QR code with accompanying text animate onto screen.

Text on screen: Please watch/listen until the end for complete Important Safety Information

Text on screen: See Important Safety Information throughout and scan the QR code to see the Full Prescribing Information, including Patient Information, or visit airsuprahcp.com.

Dr Neil Skolnik: Thank you for listening to my thoughts on shifting the asthma care paradigm with AIRSUPRA, the first and only FDA-approved anti-inflammatory rescue for asthma that treats bronchoconstriction and helps prevent asthma exacerbations. Please continue to listen for complete Important Safety Information. I encourage my primary care colleagues to visit airsuprahcp.com to learn more about the mechanism of action and clinical data and to view the full Prescribing Information, including Patient Information, for AIRSUPRA.

Graphic on screen: ISI builds along with VO.

Text on screen:

IMPORTANT SAFETY INFORMATION (Continued)

• Hypersensitivity Reactions, Including Anaphylaxis: Can occur after administration of albuterol sulfate and budesonide, components of AIRSUPRA, as demonstrated by cases of anaphylaxis, angioedema, bronchospasm, oropharyngeal edema, rash, and urticaria. Discontinue AIRSUPRA if such reactions occur

• Risk of Sympathomimetic Amines with Certain Coexisting Conditions: AIRSUPRA, like all therapies containing sympathomimetic amines, should be used with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus and in patients who are unusually responsive to sympathomimetic amines

• Hypokalemia: Beta-adrenergic agonist medicines may produce significant hypokalemia in some patients. The decrease in serum potassium is usually transient, not requiring supplementation

• Immunosuppression and Risk of Infections: Due to possible immunosuppression from the use of inhaled corticosteroids (ICS), potential worsening of infections could occur. Use with caution. A more serious or fatal course of chickenpox or measles can occur in susceptible patients

• Oropharyngeal Candidiasis: Has occurred in patients treated with ICS agents. Monitor patients periodically. Advise patients to rinse his/her mouth with water, if available, without swallowing after inhalation

• Hypercorticism and Adrenal Suppression: May occur with very high doses in susceptible individuals. If such changes occur, consider appropriate therapy

• Reduction in Bone Mineral Density: Decreases in bone mineral density have been observed with long-term administration of ICS. For patients at high risk for decreased bone mineral density, assess initially and periodically thereafter

• Glaucoma and Cataracts: Have been reported following the long-term administration of ICS, including budesonide, a component of AIRSUPRA

• Effects on Growth: Orally inhaled corticosteroids, including budesonide, may cause a reduction in growth velocity when administered to pediatric patients. The safety and effectiveness of AIRSUPRA have not been established in pediatric patients, and AIRSUPRA is not indicated for use in this population

• Most common adverse reactions (incidence ≥ 1%) are headache, oral candidiasis, cough, and dysphonia

• Drug Interactions: AIRSUPRA should be administered with caution to patients being treated with:

  • Strong cytochrome P450 3A4 inhibitors (may cause systemic corticosteroid effects)

  • Short-acting bronchodilators (concomitant use of additional beta-agonists with AIRSUPRA should be used judiciously to prevent beta-agonist overdose)

  • Beta-blockers (may block pulmonary effects of beta-agonists and produce severe bronchospasm)

  • Diuretics or non-potassium-sparing diuretics (may potentiate hypokalemia or ECG changes). Consider monitoring potassium levels

  • Digoxin (may decrease serum digoxin levels). Consider monitoring digoxin levels

  • Monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants (Use AIRSUPRA with extreme caution; may potentiate effect of albuterol on the cardiovascular system)

• Use AIRSUPRA with caution in patients with hepatic impairment, as budesonide systemic exposure may increase. Monitor patients with hepatic disease

Announcer: Hypersensitivity reactions including anaphylaxis can occur after administration of albuterol sulfate and budesonide, as demonstrated by cases of anaphylaxis, angioedema, bronchospasm, oropharyngeal edema, rash, and urticaria. Discontinue AIRSUPRA if these occur.

Like all therapies containing sympathomimetic amines, AIRSUPRA should be used with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus and those unusually responsive to sympathomimetic amines.

Beta-adrenergic agonists may produce significant hypokalemia in some patients. Decreased serum potassium is usually transient.

Due to possible immunosuppression from the use of ICS, worsening of infections can occur. A more serious or fatal course of chickenpox or measles can occur in susceptible patients.

Oropharyngeal candidiasis has occurred in patients treated with ICS agents. Monitor patients periodically. Advise patients to rinse their mouth with water without swallowing after inhalation.

Hypercorticism and adrenal suppression may occur with very high doses in susceptible patients. If these occur, consider appropriate therapy.

Decreases in bone mineral density have been observed with long-term administration of ICS. Regularly assess patients at high risk for decreased bone mineral density.

Glaucoma and cataracts have been reported following long-term administration of ICS, including budesonide.

Orally inhaled corticosteroids, including budesonide, may cause a reduction in growth velocity in pediatric patients. The safety and effectiveness of AIRSUPRA have not been established in pediatric patients and AIRSUPRA is not indicated for use in this population.

The most common adverse reactions are headache, oral candidiasis, cough, and dysphonia.

AIRSUPRA should be administered with caution to patients being treated with strong cytochrome P450 3A4 inhibitors, which may cause systemic corticosteroid effects; short-acting bronchodilators (concomitant use of additional beta-agonists with AIRSUPRA should be used judiciously to prevent beta-agonist overdose); beta-blockers, which may block pulmonary effects of beta-agonists and produce severe bronchospasm; diuretics or non-potassium-sparing diuretics, which may potentiate hypokalemia or ECG changes (consider monitoring potassium levels); digoxin, which may decrease serum digoxin levels (consider monitoring digoxin levels); mAOIs or tricyclic antidepressants. Use AIRSUPRA with extreme caution as these may potentiate the effect of albuterol on the cardiovascular system.

Use AIRSUPRA with caution in patients with hepatic impairment as budesonide systemic exposure may increase. Monitor patients with hepatic disease.

These are not all of the side effects for AIRSUPRA. Visit www.airsuprahcp.com for additional information, including full Prescribing Information and Patient Information.

Graphic on screen: QR code, its accompanying text, and information to report side effects animate onto screen.

Text on screen: Please see full Prescribing Information, including Patient Information obtained from your representative, by scanning the QR code, or by visiting airsuhprahcp.com

Text on screen: You are encouraged to report side effects related to AstraZeneca products by calling 1-800-236-9933. If you prefer to report these to the FDA, please call 1-800-FDA-1088.

Graphic on screen: Reference list animates onto screen.

Text on screen:

REFERENCES

Larsson K, Kankaanranta H, Janson C, et al. Bringing asthma care into the twenty-first century. NPJ Prim Care Respir Med. 2020;30(1):25. doi:10.1038/s41533-020-0182-2

GINA. Global Strategy for Asthma Management and Prevention, 2025. Accessed June 11, 2025. https://ginasthma.org

National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol. 2007;120(5 Suppl):S94-S138. doi:10.1016/j.jaci.2007.09.043

Gautier C, Charpin D. Environmental triggers and avoidance in the management of asthma. J Asthma Allergy. 2017:10:47-56. doi:10.2147/JAA.S121276

Partridge MR, van der MolenT, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006;6:13. doi:10.1186/1471-2466-6-13

George M, Balantac Z, Gillette C, et al. Suboptimal Control of Asthma Among Diverse Patients: A US Mixed Methods Focus Group Study. J Asthma Allergy. 2022;15:1511-1526. doi:10.2147/JAA.S377760

Kaplan A, Mitchell PD, Cave AJ, Gagnon R, Foran V, Ellis AK. Effective Asthma Management: Is It Time to Let the AIR out of SABA? J Clin Med. 2020;9(4):921.

GINA. Global Strategy for Asthma Management and Prevention, 2019. Accessed June 11, 2025. https://ginasthma.org/

AIRSUPRA® (albuterol/budesonide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2025.

US Food & Drug Administration. FDA approves drug combination treatment for adults with asthma. Published online January 11, 2023. Accessed June 11, 2025. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-combination-treatment-adults-asthma

Graphic on screen: End card animates onto screen (holds for 8 seconds).

Text on screen:

THANK YOU FOR WATCHING

Please visit https://www.airsuprahcp.com or scan this code for more information

AstraZeneca is committed to conducting business with the highest standards of integrity and professionalism.

If you have any comments that could improve the delivery of our promotional education programs, please contact AstraZeneca at 1-800-236-9933.

You are encouraged to report side effects related to AstraZeneca products by calling 1-800-236-9933. If you prefer to report these to the FDA, please call 1-800-FDA-1088.
PRN=as needed.

AIRSUPRA® (albuterol/budesonide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2025.

Please see full Prescribing Information, including Patient Information obtained from your representative or by visiting airsuprahcp.com.

AIRSUPRA is a registered trademark of the AstraZeneca group of companies.

©2025 AstraZeneca. All rights reserved. US-102772 Last Updated 9/25

ICS Exposure in Asthma Treatment Transcript

Graphic on screen: AIRSUPRA logo, video title, and a photo of Dr Wendy L. Wright, animate onto screen.

Text on screen: SUPRASESSIONS With Dr Wendy L. Wright, Adult and Family Nurse Practitioner

Graphic on screen: Dots fill the frame. Copy appears in the center and expands, pushing the dots into the corners of the frame. The dots animate in place, while particles highlight the video title.

Text on screen: SESSION 2: ICS EXPOSURE IN ASTHMA TREATMENT

ICS, inhaled corticosteroid.

Graphic on screen: Dots fill the frame, then part to reveal Dr Wright. Text builds next to Dr Wright and a line animates around the copy.

Text on screen: DR WENDY L. WRIGHT, ADULT AND FAMILY NURSE PRACTITIONER

Dr Wendy Wright: Hello, I’m Dr Wendy Wright, an adult and family nurse practitioner. Thanks so much for joining me. Today I’m going to talk about inhaled corticosteroid, or ICS, exposure in asthma treatment. Let’s start with why it’s important to consider ICS in your patient’s asthma rescue treatment.

Graphic on screen: Transition to graph that builds.

Dr Wendy Wright: For decades, patients have relied on SABA-only rescue for relief of their asthma symptoms. But SABA alone doesn’t address inflammation, leaving patients at risk of exacerbations. That’s because inflammation and symptoms vary over time and intensity. And while maintenance therapy helps address baseline inflammation, it may not always be enough to address variability in inflammation, even when patients are adherent to their maintenance therapy. This is where ICS-containing rescue comes into play.

Graphic on screen: Transition back to Dr Wright. GINA logo animates on screen.

Dr Wendy Wright: Global asthma experts from GINA (short for Global Initiative for Asthma)…

Graphic on screen: Text animates on screen, outlined by a moving line.

Text on screen: Supports an anti-inflammatory rescue approach for all adult patients with asthma

Dr Wendy Wright: …support an anti-inflammatory rescue approach for all adult patients with asthma. These experts…

Graphic on screen: Text animates on screen, outlined by a moving line.

Text on screen: GINA has recommended against SABA-only treatment of asthma in adults since 2019

SABA, short-acting β₂-agonist.

Dr Wendy Wright: …have recommended against SABA-only treatment of asthma in adults since 2019.

Graphic on screen: Transition back to Dr Wright.

Dr Wendy Wright: When choosing an anti-inflammatory rescue approach for your patients with asthma, a common question might be,…

Graphic on screen: Dots fill the frame. Copy appears in the center and expands, pushing the dots aside. A line animates around the copy. The dots float in the space around the text.

Text on screen: “HOW MUCH ICS EXPOSURE WOULD PATIENTS GET IF USING BOTH AN ICS-CONTAINING MAINTENANCE AND A RESCUE THAT INCLUDES AN ICS?”

ICS, inhaled corticosteroid.

Dr Wendy Wright: …“How much ICS exposure would patients get if using both an ICS-containing maintenance and a rescue that includes an ICS?”

Graphic on screen: Dots fill the frame. Copy appears in the center and expands, pushing the dots aside. A line animates around the copy. The dots float in the space around the text.

Text on screen: RETROSPECTIVE, REAL-WORLD CLAIMS STUDY: 2010-2017 DATA

>500,000 PATIENTS WITH ASTHMA EVALUATED ACROSS ALL SEVERITIES

Dr Wendy Wright: This question was examined in an observational, retrospective US administrative claims study that included data from more than half a million patients who were at least 12 years of age with asthma across all severities.

Graphic on screen: Dots transition to reveal Dr Wright.

Dr Wendy Wright: A key objective of this study was to estimate the daily ICS exposure that would occur if patients were to use an ICS every time they use their SABA rescue for symptoms.

Graphic on screen: Dots fill the frame and the background color lightens. Copy appears in the center and expands, pushing the dots aside as Dr Wright reads through them. A line animates around the copy. The dots float in the space around the text.

Text on screen: REAL-WORLD CLAIMS STUDY

OBSERVED ICS EXPOSURE

• Based on post-index claims for ICS-containing maintenance therapies (proportion of days covered)

• Assumes full prescription use

• Expressed as mcg/day fluticasone propionate equivalents

PROJECTED ICS EXPOSURE

• Additional as-needed ICS exposure if 50 mcg^* were added to each SABA rescue inhalation

• Estimated for the post-index year using mean SABA fills^†

^*50 mcg fluticasone propionate equivalent=80 mcg of budesonide.

^†Inhalations/day were based on 200 inhalations per canister multiplied by the mean number of post-index canisters filled.

ICS, inhaled corticosteroid; SABA, short-acting β₂-agonist.

Dr Wendy Wright: The total estimated ICS exposure was calculated by combining observed and projected ICS exposure. Observed exposure was based on post-index prescription claims, using proportion of days covered and assuming full use of the prescription fills, and was expressed as micrograms per day of fluticasone propionate equivalents. Projected exposure reflected additional ICS exposure if 50 micrograms were delivered with each SABA rescue inhalation, based on mean SABA fills in the post-index year.

Graphic on screen: A bar chart with footnotes appears on screen. Each bar animates upward sequentially from left to right until all data points are displayed.

Dr Wendy Wright: The mean total estimated ICS exposure per day was calculated by adding the observed ICS exposure resulting from maintenance therapy to the projected ICS exposure that would result if every SABA rescue inhalation was combined with an ICS. The mean total estimated ICS exposure per day is highlighted in purple.

Graphic on screen: Orange/red symbols appear above bars, and footnotes change.

Dr Wendy Wright: This study showed that the estimated total ICS exposure from the use of an ICS with a SABA as rescue therapy on top of an ICS-based maintenance therapy did not exceed the daily maximum FDA-approved ICS dosing at each step of therapy, shown in the orange and red gradients.

Graphic on screen: Chart fades out. Dots transition to reveal Dr Wright.

Dr Wendy Wright: Now we will shift to evidence from randomized clinical trials to discuss ICS-related safety of AIRSUPRA and albuterol.

Graphic on screen: Dots transition to create our branded dotted pattern in the corners of the frame and reveal the branded background color. Dots in the corners animate. AIRSUPRA logo grows into place. Text animates into frame as Dr Wright reads the text.

Text on screen: The first and only FDA-approved ANTI-INFLAMMATORY RESCUE that treats bronchoconstriction and helps prevent exacerbations

AIRSUPRA® is a combination of albuterol, a beta₂-adrenergic agonist, and budesonide, a corticosteroid, indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older.

FDA, Food and Drug Administration.

IMPORTANT SAFETY INFORMATION

• Contraindications: Hypersensitivity to albuterol, budesonide, or to any of the excipients

• Deterioration of Asthma: Asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient continues to experience symptoms after using AIRSUPRA or requires more doses of AIRSUPRA than usual, it may be a marker of destabilization of asthma and requires evaluation of the patient and their treatment regimen

Please continue to watch for full Important Safety Information.

Dr Wendy Wright: AIRSUPRA is the first and only FDA-approved anti-inflammatory rescue that treats bronchoconstriction and helps prevent exacerbations. AIRSUPRA is a combination of albuterol, a beta₂-adrenergic agonist, and budesonide, a corticosteroid, indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older.

Graphic on screen: Boxes expand into frame; text and inhaler graphics animate in.

Text on screen: AIRSUPRA contains

ALBUTEROL (SABA) for rapid bronchodilation + BUDESONIDE (ICS) to address inflammation

AIRSUPRA 90/80 mcg

2 inhalations PRN for asthma symptoms

No more than 12 inhalations in a 24-hour period

ICS, inhaled corticosteroid; PRN, as needed; SABA, short-acting β₂-agonist.

IMPORTANT SAFETY INFORMATION

• Contraindications: Hypersensitivity to albuterol, budesonide, or to any of the excipients

• Deterioration of Asthma: Asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient continues to experience symptoms after using AIRSUPRA or requires more doses of AIRSUPRA than usual, it may be a marker of destabilization of asthma and requires evaluation of the patient and their treatment regimen

Please continue to watch for full Important Safety Information.

Dr Wendy Wright: Important Safety Information.

Contraindications include hypersensitivity to albuterol, budesonide, or to any of the excipients.

Deterioration of Asthma: Asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient continues to experience symptoms after using AIRSUPRA or requires more doses of AIRSUPRA than usual, it may be a marker of destabilization of asthma and requires evaluation of the patient and their treatment regimen.

Please see additional Important Safety Information for AIRSUPRA at the end of this video.

Graphic on screen: Transition back to Dr Wright. Text animates on screen, outlined by a moving line.

Text on screen: BATURA CLINICAL TRIAL

PATIENTS WITH INTERMITTENT TO MILD PERSISTENT ASTHMA

Dr Wendy Wright: The safety and efficacy of AIRSUPRA were evaluated in a Phase IIIb, randomized, double-blind, patient-centric, event-driven exacerbation trial with a minimum duration of at least 12 weeks in 2421 patients who were at least 12 years of age with intermittent to mild persistent asthma. 26% of patients were taking SABA plus low-dose ICS maintenance therapy or leukotriene receptor antagonists, LTRAs, as their pretrial asthma therapy.

Graphic on screen: Adverse events chart with footnotes appears on screen.

Dr Wendy Wright: In this trial, common adverse reactions reported in greater than or equal to 1% of patients who used AIRSUPRA vs albuterol were headache and cough.

Graphic on screen: ICS-associated adverse events chart with footnotes appears on screen.

Dr Wendy Wright: Here we see the ICS-associated adverse events in patients with intermittent to mild persistent asthma, where ICS-associated adverse events occurred in less than 2% of the participants in each group.

Graphic on screen: Transition back to Dr Wright. Text animates on screen, outlined by a moving line.

Text on screen: MANDALA CLINICAL TRIAL

PATIENTS WITH MODERATE TO SEVERE ASTHMA

Dr Wendy Wright: AIRSUPRA was also evaluated in a Phase III, randomized, double-blind, multicenter, variable-length, exacerbation trial with a minimum duration of 24 weeks in 3040 symptomatic patients who were at least 12 years of age with moderate to severe asthma. All patients in this trial were receiving daily…

Graphic on screen: Continue with Dr Wright on screen. Text animates on screen, outlined by a moving line.

Text on screen: ICS-containing maintenance therapy taken on >75% of the days

Dr Wendy Wright: …ICS-containing maintenance therapy. Patients in this trial reported using their maintenance therapy on average more than 75% of the days.

Graphic on screen: Adverse events chart with footnotes appears on screen.

Dr Wendy Wright: In this trial, adverse events were similar for both treatment arms. The most common adverse events reported in greater than or equal to 1% of patients who used AIRSUPRA were headache, oral candidiasis, and cough.

Graphic on screen: ICS-associated adverse events chart with footnotes appears on screen.

Dr Wendy Wright: The frequency of local ICS-associated adverse events in patients with moderate to severe asthma were similar across treatment arms.

Graphic on screen: Dots fill the frame, then part to reveal Dr Wright. Text builds next to Dr Wright, and a line animates around the copy as it is being discussed.

Dr Wendy Wright: Based on what we’ve covered, let’s recap the key takeaways. We talked about the…

Text on screen: Variability in inflammation in asthma

Dr Wendy Wright: …variability in inflammation in asthma and why maintenance therapy may not always be enough to address it.

Text on screen: ICS exposure from both ICS-containing maintenance and rescue that included an ICS

Dr Wendy Wright: We also examined estimated ICS exposure from both ICS-containing maintenance and rescue if an ICS was included, based on claims data. Finally,…

Text on screen: ICS-associated adverse events in AIRSUPRA clinical trials

ICS, inhaled corticosteroid.

Dr Wendy Wright: …we discussed ICS-associated adverse events in AIRSUPRA clinical trials.

Graphic on screen: Dots in corners animate. Text and QR code animate into frame.

Text on screen: SCAN THIS CODE

TO LEARN MORE ABOUT THE FIRST AND ONLY FDA-APPROVED ANTI-INFLAMMATORY ASTHMA RESCUE AT AIRSUPRAHCP.COM

FDA, Food and Drug Administration.

Dr Wendy Wright: Scan this code to learn more about the first and only FDA-approved anti-inflammatory asthma rescue at airsupraHCP.com.

Graphic on screen: Scrolling Important Safety Information.

Text on screen:

IMPORTANT SAFETY INFORMATION

• Contraindications: Hypersensitivity to albuterol, budesonide, or to any of the excipients

• Deterioration of Asthma: Asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient continues to experience symptoms after using AIRSUPRA or requires more doses of AIRSUPRA than usual, it may be a marker of destabilization of asthma and requires evaluation of the patient and their treatment regimen

• Paradoxical Bronchospasm: AIRSUPRA can produce paradoxical bronchospasm, which may be life threatening. Discontinue AIRSUPRA immediately and institute alternative therapy if paradoxical bronchospasm occurs. It should be recognized that paradoxical bronchospasm, when associated with inhaled formulations, frequently occurs with the first use of a new canister

• Cardiovascular Effects: AIRSUPRA, like other drugs containing beta₂-adrenergic agonists, can produce clinically significant cardiovascular effects in some patients, as measured by pulse rate, blood pressure, and/or other symptoms. If such effects occur, AIRSUPRA may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST-segment depression. Therefore, AIRSUPRA, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension

• Do Not Exceed Recommended Dose: Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs

• Hypersensitivity Reactions, Including Anaphylaxis: Can occur after administration of albuterol sulfate and budesonide, components of AIRSUPRA, as demonstrated by cases of anaphylaxis, angioedema, bronchospasm, oropharyngeal edema, rash, and urticaria. Discontinue AIRSUPRA if such reactions occur

• Risk of Sympathomimetic Amines with Certain Coexisting Conditions: AIRSUPRA, like all therapies containing sympathomimetic amines, should be used with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus and in patients who are unusually responsive to sympathomimetic amines

• Hypokalemia: Beta-adrenergic agonist medicines may produce significant hypokalemia in some patients. The decrease in serum potassium is usually transient, not requiring supplementation

• Immunosuppression and Risk of Infections: Due to possible immunosuppression from the use of inhaled corticosteroids (ICS), potential worsening of infections could occur. Use with caution. A more serious or fatal course of chickenpox or measles can occur in susceptible patients

• Oropharyngeal Candidiasis: Has occurred in patients treated with ICS agents. Monitor patients periodically. Advise patients to rinse his/her mouth with water, if available, without swallowing after inhalation

• Hypercorticism and Adrenal Suppression: May occur with very high doses in susceptible individuals. If such changes occur, consider appropriate therapy

• Reduction in Bone Mineral Density: Decreases in bone mineral density have been observed with long-term administration of ICS. For patients at high risk for decreased bone mineral density, assess initially and periodically thereafter

• Glaucoma and Cataracts: Have been reported following the long-term administration of ICS, including budesonide, a component of AIRSUPRA

• Effects on Growth: Orally inhaled corticosteroids, including budesonide, may cause a reduction in growth velocity when administered to pediatric patients. The safety and effectiveness of AIRSUPRA have not been established in pediatric patients, and AIRSUPRA is not indicated for use in this population

• Most common adverse reactions (incidence ≥ 1%) are headache, oral candidiasis, cough, and dysphonia

• Drug Interactions: AIRSUPRA should be administered with caution to patients being treated with:

  • Strong cytochrome P450 3A4 inhibitors (may cause systemic corticosteroid effects)

  • Short-acting bronchodilators (concomitant use of additional beta-agonists with AIRSUPRA should be used judiciously to prevent beta-agonist overdose)

  • Beta-blockers (may block pulmonary effects of beta-agonists and produce severe bronchospasm)

  • Diuretics or non-potassium-sparing diuretics (may potentiate hypokalemia or ECG changes). Consider monitoring potassium levels

  • Digoxin (may decrease serum digoxin levels). Consider monitoring digoxin levels

  • Monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants (Use AIRSUPRA with extreme caution; may potentiate effect of albuterol on the cardiovascular system)

• Use AIRSUPRA with caution in patients with hepatic impairment, as budesonide systemic exposure may increase. Monitor patients with hepatic disease

INDICATION

AIRSUPRA is a combination of albuterol, a beta₂-adrenergic agonist and budesonide, a corticosteroid, indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older.

You are encouraged to report negative side effects of AstraZeneca prescription drugs by calling 1-800-236-9933. If you prefer to report these to the FDA, call 1-800-FDA-1088.

Please see full Prescribing Information, including Patient Information, by visiting airsupraHCP.com.

Announcer: AIRSUPRA Important Safety Information.

AIRSUPRA is contraindicated in patients with hypersensitivity to albuterol, budesonide, or any excipients.

Asthma may deteriorate acutely or chronically. Continued symptoms after AIRSUPRA or increasing doses of AIRSUPRA may be a marker of asthma destabilization and require evaluation of the patient and their treatment regimen.

AIRSUPRA can produce paradoxical bronchospasm, which may be life threatening. Discontinue AIRSUPRA immediately if paradoxical bronchospasm occurs. Paradoxical bronchospasm frequently occurs with the first use of a new canister of an inhaled formulation.

Drugs containing beta₂-adrenergic agonists can produce clinically significant cardiovascular effects in some patients. If these occur, consider discontinuation of AIRSUPRA. Beta-agonists have also been reported to produce ECG changes such as T-wave flattening, QTc interval prolongation, and ST-segment depression. Therefore, as with all sympathomimetic amines, AIRSUPRA should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.

Do not exceed recommended dose. Clinically significant cardiovascular effects and fatalities have been reported with excessive use of inhaled sympathomimetic drugs.

Hypersensitivity reactions including anaphylaxis can occur after administration of albuterol sulfate and budesonide, as demonstrated by cases of anaphylaxis, angioedema, bronchospasm, oropharyngeal edema, rash, and urticaria. Discontinue AIRSUPRA if these occur.

Like all therapies containing sympathomimetic amines, AIRSUPRA should be used with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus and those unusually responsive to sympathomimetic amines.

Beta-adrenergic agonists may produce significant hypokalemia in some patients. Decreased serum potassium is usually transient.

Due to possible immunosuppression from the use of ICS, worsening of infections can occur. A more serious or fatal course of chickenpox or measles can occur in susceptible patients.

Oropharyngeal candidiasis has occurred in patients treated with ICS agents. Monitor patients periodically. Advise patients to rinse their mouth with water without swallowing after inhalation.

Hypercorticism and adrenal suppression may occur with very high doses in susceptible patients. If these occur, consider appropriate therapy.

Decreases in bone mineral density have been observed with long-term administration of ICS. Regularly assess patients at high risk for decreased bone mineral density.

Glaucoma and cataracts have been reported following long-term administration of ICS, including budesonide.

Orally inhaled corticosteroids, including budesonide, may cause a reduction in growth velocity in pediatric patients. The safety and effectiveness of AIRSUPRA have not been established in pediatric patients and AIRSUPRA is not indicated for use in this population.

The most common adverse reactions are headache, oral candidiasis, cough, and dysphonia.

AIRSUPRA should be administered with caution to patients being treated with strong cytochrome P450 3A4 inhibitors, which may cause systemic corticosteroid effects; short-acting bronchodilators (concomitant use of additional beta-agonists with AIRSUPRA should be used judiciously to prevent beta-agonist overdose); beta-blockers, which may block pulmonary effects of beta-agonists and produce severe bronchospasm; diuretics or non-potassium-sparing diuretics, which may potentiate hypokalemia or ECG changes (consider monitoring potassium levels); digoxin, which may decrease serum digoxin levels (consider monitoring digoxin levels); mAOIs or tricyclic antidepressants. Use AIRSUPRA with extreme caution as these may potentiate the effect of albuterol on the cardiovascular system.

Use AIRSUPRA with caution in patients with hepatic impairment as budesonide systemic exposure may increase. Monitor patients with hepatic disease.

These are not all of the side effects for AIRSUPRA. Visit www.airsuprahcp.com for additional information, including full Prescribing Information and Patient Information.

Graphic on screen: Reference list animates in. AstraZeneca logo animates in the bottom left corner.

Text on screen:

REFERENCES

AIRSUPRA® (albuterol/budesonide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2025.

Chu EK, Drazen JM. Asthma: one hundred years of treatment and onward. Am J Respir Crit Care Med. 2005;171(11):1202-1208. doi:10.1164/rccm.200502-2570E

Data on File. REF-174347. AstraZeneca Pharmaceuticals LP.

Data on File. REF-202630. AstraZeneca Pharmaceuticals LP.

Data on File. REF-267550. AstraZeneca Pharmaceuticals LP.

Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2025. Accessed January 12, 2026.www.ginasthma.org

Kaplan A, Mitchell PD, Cave AJ, Gagnon R, Foran V, Ellis AK. Effective asthma management: is it time to let the AIR out of SABA? J Clin Med. 2020;9(4):921. doi:10.3390/jcm9040921

LaForce C, Albers F, Danilewicz A, et al; BATURA Investigators. As-needed albuterol-budesonide in mild asthma. N Engl J Med. 2025;393(2):113-124. doi:10.1056/NEJMoa2504544

Lanz M, Pollack M, Gilbert, Gandhi H, Tkacz J, Lugogo N. Asthmatic patients are at risk for exacerbations irrespective of control, maintenance adherence, or disease severity. Poster presented at: American College of Allergy, Asthma & Immunology Annual Scientific Meeting; November 10-14, 2022; Louisville, KY.

Larsson K, Kankaanranta H, Janson C, et al. Bringing asthma care into the twenty-first century. NPJ Prim Care Respir Med. 2020;30(1):25. doi:10.1038/s41533-020-0182-2

Lugogo N, Gilbert I, Pollack M, Gandhi H, Tkacz J, Lanz MJ. Estimating inhaled corticosteroid exposure from short-acting β₂-agonist-inhaled corticosteroid rescue. J Asthma Allergy. 2023;16:579-584. doi:10.2147/JAA.S408504

Papi A, Chipps BE, Beasley R, et al. Albuterol-budesonide fixed-dose combination rescue inhaler for asthma. N Engl J Med. 2022;386(22):2071-2083. doi:10.1056/NEJMoa2203163

Stein SW, Thiel CG. The history of therapeutic aerosols: a chronological review. J Aerosol Med Pulm Drug Deliv. 2017;30(1):20-41. doi:10.1089/jamp.2016.1297

US Food and Drug Administration. FDA approves drug combination treatment for adults with asthma. Published January 11, 2023. Accessed January 12, 2026. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-combination-treatment-adults-asthma

AIRSUPRA is a registered trademark of the AstraZeneca group of companies.

©2026 AstraZeneca. All rights reserved. US-107558 Last Updated 6/26